1. Chang AE, Li Q, Jiang G, Sayre DM, Braun TM, Redman BG (2003) Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer. J Clin Oncol 21:884–890
2. Nijhuis EWP, Wiel-van Kemenade EVD, Figdor CG, Van Lier RAW (1990) Activation and expansion of tumour-infiltrating lymphocytes by anti-CD3 and anti-CD28 monoclonal antibodies. Cancer Immunol Immunother 32:245–250
3. Alexander JP, Kudoh S, Melsop KA, Hamilton TA, Edinger MG, Tubbs RR, Sica D, Tuason L, Klein E, Bukowski RM, Finke JH (1993) T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors. Cancer Res 53:1380–1387
4. Correa MR, Ochoa AC, Ghosh P, Mizoguchi H, Harvey L, Longo DL (1997) Sequential development of structural and functional alterations in T cells from tumor-bearing mice. J Immunol 158:5292–5296
5. Danna EA, Sinha P, Gilbert M, Clements VK, Pulaski BA, Ostrand-Rosenberg S (2004) Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease. Cancer Res 64:2205–2211